ABSTRACT
The relationship between folic acid and S-adenosylhomocysteine (SAH) is controversial. This study aims to explore the effect of different doses of folic acid supplementation on SAH levels in hypertensive patients and the modification of methylene-tetrahydrofolate reductase (MTHFR) C677T gene polymorphism. A randomized, double-blind, controlled clinical trial was conducted. Hypertensive patients aged 45-75 years without a history of stroke and cardiovascular disease were selected, who were randomly assigned to one of 8 dose groups. This trial has been registered with Trial Number: ChiCTR1800016135. In the total population, folic acid supplementation of 0.4-2.0â mg/day had no effect on SAH level (ßâ =â 0.47, 95% CI: -0.86-1.79, pâ =â 0.491), while folic acid supplementation of 2.4â mg/day significantly increased SAH level (ßâ =â 1.93, 95% CI: 0.22-3.64, pâ =â 0.027). Stratified analysis found that MTHFR C677T genotype CC supplemented with 2.4â mg/day folic acid had no effect on SAH level (ßâ =â 0.30, 95% CI: -2.74-3.34, pâ =â 0.847), while CT and TT genotype supplemented with 2.4â mg/day folic acid showed a significant increase in SAH level (CT: ßâ =â 2.98, 95% CI: 0.34-5.62, pâ =â 0.027; TT: ßâ =â 3.00, 95% CI: -0.51-6.51, pâ =â 0.095; CT combined with TT: ßâ =â 2.99, 95% CI: 0.90-5.09, pâ =â 0.005). In conclusion, supplementation of 2.4â mg/day folic acid can lead to increased SAH levels, especially in MTHFR C677T genotype CT and TT.
ABSTRACT
These active components and monomes inhibit thrombosis aimed directly at activation, adhesiveness and aggregation of platelet, thus preventing and curing ischemic cardiovascular and cerebrovascular diseases. Here we summarized the effect of active components and monomes of the traditional Chinese medicine targeted platelet on ischemic cardiovascular and cerebrovascular diseases, to provide references for drug investigation and clinical application.